Next Technology Holding Inc. shares rise 6.38% premarket after Creative Medical Technology Holdings, Inc. announced FDA Fast Track designation for CELZ-201-DDT.

Next Technology Holding Inc. rose 6.38% in premarket trading. The company's stock price increase may be attributed to the positive news that Creative Medical Technology Holdings, Inc. has received Fast Track designation from the FDA for its lead investigational therapy, CELZ-201-DDT, for the treatment of degenerative disc disease. This designation enables the company to benefit from accelerated FDA interactions and rolling Biologics License Application (BLA) submissions, potentially expediting the path to market and patient access.